Angiomyolipoma future or investigational therapies: Difference between revisions
No edit summary |
|||
| Line 5: | Line 5: | ||
[[Rapamycin]] and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when ''TSC1'' and ''TSC2'' genes are broken.<ref name=Bissler2010>Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.</ref> | [[Rapamycin]] and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when ''TSC1'' and ''TSC2'' genes are broken.<ref name=Bissler2010>Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.</ref> | ||
==Future Therapies== | ==Future Therapies== | ||
=== | ===Rapamycin=== | ||
[[Rapamycin]] and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when ''TSC1'' and ''TSC2'' genes are broken.<ref name=Bissler2010>Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.</ref> | [[Rapamycin]] and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when ''TSC1'' and ''TSC2'' genes are broken.<ref name=Bissler2010>Bissler JJ, Henske EP. Renal Manifestations of Tuberous Sclerosis Complex. In: Kwiatkowski DJ, Wiittlemore DJ, Thiele EA, editors. Tuberous Sclerosis Complex: Genes, Clinical Features and Therapeutics. Wiley-VCH Verlag GmbH; 2010. p. 321–325. ISBN 3-527-32201-9.</ref> | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 20:48, 1 October 2015
|
Angiomyolipoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Angiomyolipoma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Angiomyolipoma future or investigational therapies |
|
Angiomyolipoma future or investigational therapies in the news |
|
Risk calculators and risk factors for Angiomyolipoma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
Rapamycin and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when TSC1 and TSC2 genes are broken.[1]
Future Therapies
Rapamycin
Rapamycin and related drugs have been studied for their effect on angiomyolipomas due to their action on the pathways that are disrupted when TSC1 and TSC2 genes are broken.[1]